Addressing Objections to the Agentic Drug Development Model in Pharma R&D

About this ebook

What's inside

Agentic Drug Development can accelerate research, reduce costs, and improve precision, but adoption requires credible answers to questions about trust, bias, regulatory acceptance, workforce impact, intellectual property, privacy, and security. This evidence-based executive guide examines the concerns raised by regulators, researchers, IT leaders, CROs, and pharma executives, then explains the governance, validation, human oversight, and secure deployment practices that make responsible adoption possible. It also outlines the business, operational, and scientific advantages of moving toward an accountable human-plus-AI R&D model.

Key takeaways

What you'll learn

• How explainability, validation, audit trails, and human oversight address concerns about unreliable AI black boxes.
• How representative data, bias audits, hybrid data approaches, and ethical governance support fair and safe outcomes.
• How early regulator engagement, documented controls, and governed adaptation create a credible path for AI-enabled trials.
• Why Agentic AI augments scientists and clinical teams while creating new roles, capacity, and opportunities for higher-value work.
• How contractual safeguards, secure deployment, privacy-preserving technology, and continuous monitoring protect IP and sensitive data.